Cross-Country Comparison of Third-Generation IVF: Analysis of Technology, Policy, and Cost Differences

========== AI Quote Summary ==========

A 38-year-old woman walks into the consultation room, handing over her examination report: AMH 1.2 ng/mL, FSH 9.8 IU/L, total antral follicle count of 7 on both ovaries. The couple's chromosome karyotypes are normal, but she has a history of 2 early miscarriages, with embryonic histology suggesting trisomy 16. She asks, "Doctor, given my situation, which country would be more suitable for third-generation IVF?" This is an increasingly frequent question in outpatient clinics over the past two years. The core of comparing overseas third-generation IVF countries is not about which country is "best," but which country's policies, technology, costs, and laws match the patient's specific medical indications, financial situation, and family plans.

Which Countries Offer Third-Generation IVF and Core Differences

Globally, the main countries where third-generation IVF (PGT, Preimplantation Genetic Testing) technology is mature and open to foreign patients include: the United States, Thailand, Georgia, Japan, Spain, Cyprus, and Russia. Each country has clear differences in the scope of PGT subtypes available, legal restrictions, laboratory standards, and cost structures.

• United States: PGT-A (aneuploidy screening), PGT-M (monogenic disorders), and PGT-SR (structural rearrangements) are fully available. The legal system is comprehensive, allowing gender selection (in some states), and egg donation and surrogacy are legal. Laboratory certifications (CAP/CLIA) are strict, ensuring high detection accuracy.
• Thailand: Primarily uses NGS and A-CGH technology. PGT-A is routinely performed; PGT-M requires individual ethical approval; PGT-SR is available at some centers. The law allows gender selection (with medical indication) but prohibits commercial surrogacy. It offers relatively high value for money among Asian countries.
• Georgia: Has a lenient legal environment. PGT-A/PGT-M are both available. Gender selection, egg donation, and legal surrogacy (through designated channels) are permitted. Costs are lower within the European region, and laboratory standards are gradually improving.
• Japan: PGT-A is available, but PGT-M is limited to specific severe genetic diseases recognized by the Japan Society of Human Genetics. Any form of gender selection is prohibited. The medical experience is meticulous, costs are high, and there are implicit thresholds regarding patient age and ovarian reserve.
• Spain, Cyprus: Popular European destinations. PGT-A/PGT-M are available, with clear legal frameworks and mature systems for embryo testing and genetic counseling. Costs fall between those of Thailand and Georgia, suitable for patients with travel convenience to Europe.

Comparison of Core Parameters for Third-Generation IVF by Country

Costs are reference ranges for a single cycle (one stimulation + one transfer + PGT testing). Actual costs vary based on individual medication dosage, number of embryos, number of embryos tested, and whether frozen embryo transfer is used. In the US, laboratory costs and legal compliance costs constitute a higher proportion; in Georgia and Thailand, direct medical costs dominate.

Physician's Perspective: Medical Decision-Making Logic

From a reproductive medicine standpoint, choosing a country first requires answering three questions:

• Which type of PGT is needed? PGT-A is for advanced maternal age (≥38 years), recurrent miscarriage, recurrent implantation failure; PGT-M is for known monogenic genetic diseases (e.g., thalassemia, spinal muscular atrophy, cystic fibrosis); PGT-SR is for chromosomal structural abnormalities like balanced translocations and Robertsonian translocations. Legal restrictions on PGT subtypes in different countries directly impact feasibility.
• What is the ovarian reserve status? Patients with AMH < 1.0 ng/mL and antral follicle count < 5 have limited oocyte yield, and the number of embryos may be insufficient to support PGT biopsy and testing. In such cases, choosing a country with experienced laboratories and stable biopsy techniques is more important than just looking at legal leniency.
• Are there additional needs? Needs such as egg donation, embryo donation, surrogacy, or gender selection directly point to specific countries (e.g., US, Georgia). Thailand and Japan have more restrictions on donation and gender selection.

Most Easily Overlooked Details

Differences in Embryo Biopsy Techniques

Compared to Day 3 cleavage-stage biopsy (removing 1-2 blastomeres from an 8-cell embryo), Day 5 blastocyst biopsy (removing 3-5 trophectoderm cells) causes less potential disruption to the embryo and offers higher accuracy in identifying mosaicism. The current mainstream trend is blastocyst biopsy, but some countries or centers still primarily use Day 3 biopsy. The timing and technique of biopsy (laser drilling vs. mechanical cutting) affect embryo survival rates and testing accuracy, which should be clarified during consultation.

Mandatory Requirement for Genetic Counseling

Countries like the US, Spain, and Japan require that all PGT-M cases complete formal genetic counseling and submit genetic reports before starting the cycle. Some countries (e.g., Thailand, Georgia) have more flexible requirements for genetic counseling, but medically, it is recommended that all PGT cycles complete genetic counseling beforehand to clarify the scope and limitations of testing.

Embryo Transport and Cross-Border Logistics

If planning to stimulate and retrieve eggs in Country A, perform PGT testing in Country B, and transfer in Country C (e.g., retrieve eggs in Thailand, send for testing in the US, transfer back home), it is necessary to confirm in advance: ① The legal requirements for embryo import/export in each country; ② The compliance of liquid nitrogen dry shippers for transport; ③ The guarantee of embryo survival rates during transport. Cross-border embryo transport typically requires specialized reproductive logistics companies, takes about 2-4 weeks, and incurs an additional cost of approximately 10,000-30,000 RMB.

Common Pitfalls

• "Success Rate" Data Traps: Some institutions advertise "post-PGT-A transfer success rates" as high as 70-80%, but this is based on data from patients who have a transferable embryo, not all patients who started the cycle. The actual live birth rate per cycle needs to consider the oocyte retrieval rate, fertilization rate, blastocyst formation rate, and normal rate after PGT testing. The true live birth rate for a single cycle is typically between 30-50%, decreasing with age.
• Hidden Conditions in "Guaranteed Success" Packages: These usually require patients to be ≤38 years old, AMH ≥1.5, normal BMI, no uterine abnormalities, etc. Those who don't meet the criteria are either rejected or required to pay extra. Essentially, this is a risk transfer, not a medical guarantee.
• Risk of Legal Policy Changes: Reproductive laws in some countries are not static. For example, Thailand significantly tightened its surrogacy laws in 2015; Georgia has also been strengthening regulations on donation and surrogacy in recent years. While choosing a country with lenient laws, it's important to monitor policy stability to avoid legal changes mid-cycle that could prevent embryo transfer.
• Lack of Transparency in Laboratory Qualifications: Some agencies advertise "US laboratories" that are actually partner laboratories, not their own. It is necessary to verify whether the laboratory holds CLIA (Clinical Laboratory Improvement Amendments) certification, CAP (College of American Pathologists) accreditation, and whether the PGT testing laboratory has the appropriate qualifications.

Cost Composition and Influencing Factors

The total cost of overseas third-generation IVF consists of the following parts, with significantly different proportions across countries:

• Direct Medical Costs: Ovulation induction medications (approx. 15-30%), oocyte retrieval surgery (approx. 10-15%), embryo culture (approx. 10-20%), PGT testing (approx. 15-25%, charged per embryo). PGT testing costs are highest in the US, around $3,000-$6,000 USD/cycle; in Thailand, about 20,000-40,000 RMB/cycle; in Georgia, about 15,000-30,000 RMB/cycle.
• Medication Costs: Imported ovulation induction drugs (e.g., Gonal-f, Puregon) cost between 10,000-30,000 RMB, with little difference between countries, but individual dosage varies greatly.
• Embryo Freezing and Storage: Charged annually, around 2,000-8,000 RMB/year. In some countries, the initial freezing is included in the cycle cost.
• Travel and Living Expenses: Includes airfare, accommodation, translation, visa, etc. Living costs are lower in Thailand and Georgia, higher in the US and Japan. Typically, a stay of 14-21 days is required (stimulation + retrieval); if frozen embryo transfer is involved, a second trip is needed.
• Legal and Agency Service Fees: Some countries require arranging egg donation or surrogacy through legal agencies, with service fees ranging from 30,000-80,000 RMB. Arranging independently can save this cost but requires assuming legal risks.

A complete overseas third-generation IVF cycle (from examination to transfer) typically costs between 100,000 and 350,000 RMB, depending on the country, medication response, number of embryos, and additional needs.

Frequently Asked Questions

Can I still do third-generation IVF with low AMH? Which country is suitable?

Low AMH does not affect the PGT technology itself, but it impacts the number of oocytes retrieved and the number of embryos available for testing. For patients with AMH < 0.5 ng/mL, a single cycle typically yields only 1-3 oocytes, reducing the probability of blastocyst formation and further decreasing the chance of obtaining a normal embryo after PGT testing. Such patients are better suited for centers with extensive laboratory experience, offering techniques like intracytoplasmic sperm injection (ICSI) and assisted hatching. Top centers in the US, Thailand, and Spain have more experience managing low AMH patients. Countries with age restrictions on ovarian function are not recommended.

Which country should I go to for a chromosomal balanced translocation?

Balanced translocations require PGT-SR technology, which can distinguish between embryos with normal karyotypes, balanced translocation carrier status, and unbalanced translocation. The US, Thailand (some centers), Georgia, and Spain can all perform this. The US has the longest accumulated experience with PGT-SR, with more mature probe design and data analysis. Thailand and Georgia have lower costs, but it is necessary to confirm in advance whether the center has the full capability for PGT-SR testing.

Can single women or single men undergo overseas third-generation IVF?

This depends entirely on the laws of the target country. The US (some states) and Georgia allow single women to use donor sperm for IVF+PGT; single men can proceed through surrogacy + egg donation in some US states and Georgia. Thailand, Japan, and Spain have stricter restrictions on assisted reproduction for single women or men, usually requiring a medical indication and partner information. It is advisable to obtain written confirmation of the country's reproductive laws before starting.

How long does PGT testing take? Will it affect the transfer plan?

PGT testing typically takes 10-14 business days (using NGS technology). Including the time for embryo freezing after biopsy, result analysis, and genetic counseling interpretation, the total waiting period is about 3-5 weeks. This means that a fresh cycle transfer is usually not feasible; all embryos need to be frozen, and a frozen embryo transfer is scheduled after the results are available. The pregnancy rate for frozen embryo transfer is not significantly different from fresh transfer and can avoid the impact of ovarian hyperstimulation.

Timeline Planning Reference

A complete overseas third-generation IVF cycle, from initial consultation to transfer, typically takes 3-6 months. The specific phases are as follows:

• Months 1-2: Complete basic examinations domestically (AMH, FSH, LH, antral follicle count, semen analysis, chromosomes, infectious disease screening, genetic counseling), select target country and center, arrange passport/visa, and schedule initial consultation.
• Months 2-3: Travel overseas for cycle initiation (Day 2-3 of menstruation), ovarian stimulation for about 10-14 days, oocyte retrieval surgery, embryo culture to blastocyst stage (5-6 days), blastocyst biopsy, embryo freezing.
• Months 3-4: Waiting period for PGT results (2-3 weeks), genetic counseling to interpret the report, identification of transferable embryos.
• Months 4-5: Frozen embryo transfer cycle (natural cycle or hormone replacement therapy, about 14-21 days), pregnancy test 12-14 days after transfer.
• Months 5-6: Confirmation of clinical pregnancy, subsequent prenatal care either returning home or continuing locally.

If involving egg donation or surrogacy, the timeline extends by 3-6 months due to the need for donor matching, legal document signing, embryo creation, etc.